Mark S. Silverberg

Mark S. Silverberg

Auto-generated profile, based on publicly available information

Mark S. Silverberg

Inflammatory Bowel Disease Centre Mount Sinai Hospital Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
AMAylia Mohammadi
Aylia Mohammadi
OKOrlaith B Kelly
Orlaith B Kelly
MFMelissa Filice
Melissa Filice
BKBoyko Kabakchiev
Boyko Kabakchiev
MSMichelle I Smith
Michelle I Smith
MSMark S Silverberg
Mark S Silverberg
MicroRNAs [miRNAs] have emerged as important regulators in inflammatory bowel disease [IBD]. This study investigated differential expression of miRNAs across clinical phenotypes in a well-characterized cohort of IBD patients and healthy controls [HCs]. A cohort of Crohn’s disease [CD] and ulcerative colitis [UC] patients and HCs was prospectively accrued. Total RNA was extracted from peripheral blood mononuclear cells for all subjects. miRNA expression was measured using NanoString technologies. The subjects were stratified according to disease activity and location. Statistical significance was assessed per miRNA across outcomes and corrected for multiple testing. miRNA regulation of transcription of important results was confirmed in vitro by a dual luciferase reporter assay and autophagy function was evaluated using immunofluorescence imaging of LC3 puncta in HeLa cells. In total, 120 subjects were enrolled. Seventy-four miRNAs were differentially expressed across CD, UC and HCs. Comparing quiescent CD [CDq] with HCs we found ten miRNAs upregulated in CDq. When comparing colonic CD [CCD] to UC, seven miRNAs were upregulated in CCD. The most differentially expressed miRNA in CCD vs UC was miR-874-3p, and we showed its possible utility as a biomarker of differential diagnosis. We showed miR-874-3p targets ATG16L1 and reduces its expression in vitro. An miR-874-3p mimic dysregulates autophagy by a reduction of LC3 in vitro. We identified unique miRNA signatures expressed in distinct IBD phenotypes. These associations highlight pathways dysregulated by aberrant miRNA expression, revealing possible mechanisms underlying the pathophysiology of IBD, but also suggest a cluster of miRNAs as readily accessible biomarkers to aid in differential diagnosis.

1 August 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
ADand Marla C. Dubinsky
and Marla C. Dubinsky
RCRory Collins
Rory Collins
MAMaria T. Abreu
Maria T. Abreu
VJVipul Jairath
Vipul Jairath
JLJames D. Lewis
James D. Lewis
EZEllen Zigmont
Ellen Zigmont
Participants completed a survey focused on challenges in the conduct of clinical trials in IBD. The results showed that the greatest challenge in designing and completing studies in IBD was patient recruitment, Danese S. Schabel E. Ainsworth M.A. et al. Challenges and opportunities for IBD drug development: from early stage to regulatory approval. Gut. 2020; 69 : 1157-1161 Crossref PubMed Scopus (4) Google Scholar and it was also noted that the greatest opportunity was innovation in study design. The survey also collected opinions on the relative importance of induction and maintenance endpoints for clinical trials in IBD, and clinical remission was viewed the most important endpoint for both induction and maintenance.

6 January 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
NCNiels Vande Casteele
Niels Vande Casteele
MAMaria T. Abreu
Maria T. Abreu
SFSarah Flier
Sarah Flier
KPKonstantinos Papamichael
Konstantinos Papamichael
FRFlorian Rieder
Florian Rieder
ACAdam S. Cheifetz
Adam S. Cheifetz
Therapeutic drug monitoring (TDM) with measurement of serum drug and antidrug antibodies (ADAb) is used widely to confirm therapeutic exposure, rule out immunogenicity, and optimize treatment of biologics in patients with inflammatory bowel diseases.1 A recent genome-wide association study found the variant HLA-DQA1∗05 to increase the risk of development of antibodies against infliximab (IFX) and adalimumab (ADM) 2-fold, regardless of concomitant immunomodulator use.2,3 However, there is currently limited evidence showing whether patients who develop antibodies to 1 anti-tumor necrosis factor (TNF) are prone to develop antibodies to the subsequent anti-TNF. Our aim was to investigate the risk of subsequent antibody development in cases (with ADAb to prior anti-TNF) versus control subjects (without ADAb to prior anti-TNF) using a large cohort of patients with inflammatory bowel diseases who underwent TDM with a drug-tolerant assay.

26 December 2017 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
TGTomer Greener
Tomer Greener
KBKaren Boland
Karen Boland
ASA Hillary Steinhart
A Hillary Steinhart
MSMark S Silverberg
Mark S Silverberg
Golimumab is approved for the treatment of moderate-to-severely active ulcerative colitis. However, there have been no formal trials to date to assess its utility in Crohn’s disease (CD). Our aim was to determine the efficacy and safety of golimumab in patients with anti–TNF refractory CD. Patients with CD treated with golimumab between 2010 and 2017 were included in a retrospective observational study. The vast majority of patients failed 2 anti-TNFs agents. Clinical response was defined as a significant reduction in symptoms and biochemical markers of CD, and no requirement for surgery or introduction of immune-suppressants. Forty-five patients were included, with a median follow-up of 22 months (interquartile range 12–34) following initiation of golimumab. Induction and maintenance regimens were generally higher than standard dosing with first month cumulative doses of 400 mg and above in 75% of the patients. Monthly maintenance doses 200 mg was administered in 52% of patients. Clinical response at 3 months was achieved in 35/45 (77.7%) patients. The cumulative probabilities that patients with an initial response maintained their clinical response for 12 and 36 months after introduction of golimumab were 81% and 64%, respectively. Endoscopic improvement and mucosal healing at 12 months was achieved in 73% and 47% of patients, respectively. This study demonstrates the efficacy of golimumab in anti-TNF refractory CD patients. Further studies should be performed in CD to formally assess the efficacy of golimumab in a randomized controlled trial and to establish the optimal dosing regimen.

17 June 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
MBMichiel T.J. Bak
Michiel T.J. Bak
KDKarlijn Demers
Karlijn Demers
NHNassim Hammoudi
Nassim Hammoudi
MAMatthieu Allez
Matthieu Allez
MSMark S. Silverberg
Mark S. Silverberg
AVAnnemarie C. de Vries
Annemarie C. de Vries
BackgroundRisk stratification for endoscopic post-operative recurrence (ePOR) in Crohn's disease (CD) is required to identify patients who would benefit most from initiation of prophylactic medication and intensive monitoring of recurrence.AimsTo assess the current evidence on patient-related, microbial, surgical and histopathological risk factors for ePOR in patients with CD after ileocolic (re-)resection.MethodsMultiple online databases (Embase, MEDLINE, Web of Science and Cochrane Library) were searched up to March 2024. Studies with reported associations of patient-related, microbial, surgical and/or histopathological factors for ePOR (i.e., Rutgeerts' score >= i2 or modified Rutgeerts' score >= i2a) were included. The risk of bias was assessed with the Newcastle-Ottawa Scale for observational cohort studies and case-control studies.ResultsIn total, 47 studies were included (four RCTs, 29 cohort studies, 12 case-control studies, one cross-sectional study and one individual participant data meta-analysis) including 6006 patients (median sample size 87 patients [interquartile range 46-170]). Risk of bias assessment revealed a poor quality in 41% of the studies. An association was reported in multiple studies of ePOR with active smoking at and post-surgery, male sex and prior bowel resection. A heterogeneous association with ePOR was reported for other risk factors included in the current guidelines (penetrating disease, perianal disease, younger age, extensive small bowel disease and presence of granulomas in the resection specimen or myenteric plexitis in the resection margin), and other patient-related, microbial, surgical and histopathological factors.ConclusionRisk factors for ePOR in international guidelines are not consistently reported as risk factors in current literature except for active smoking and prior bowel resection. To develop evidence-based, personalised strategies, large prospective studies are warranted to identify risk factors for ePOR. Validation studies of promising (bio)markers are also required. Risk factors for ePOR in international guidelines are not consistently reported as risk factors in the current literature except for active smoking and a prior bowel resection. To develop evidence-based and personalised strategies, future large prospective studies are warranted for the identification of risk factors for ePOR in patients with CD. In addition, validation studies of promising (bio)markers are required.image

21 October 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
SNSiew C Ng
Siew C Ng
JMJoyce Wing Yan Mak
Joyce Wing Yan Mak
LHLara Hitz
Lara Hitz
YCYehuda Chowers
Yehuda Chowers
CBCharles N Bernstein
Charles N Bernstein
MSMark S Silverberg
Mark S Silverberg
Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 position statements, based on an online survey, that focus on how to prioritise endoscopies in IBD patients during the COVID-19 pandemic, alternative modes for disease monitoring, and ways to triage the high number of postponed endoscopies after the pandemic. We propose to pre-screen patients for suspected or confirmed COVID-19 and test for SARS-CoV-2 before endoscopy if available. High priority endoscopies during pandemic include acute gastrointestinal bleed, acute severe ulcerative colitis, new IBD diagnosis, cholangitis in primary sclerosing cholangitis, and partial bowel obstruction. Alternative modes of monitoring using clinical symptoms, serum inflammatory markers, and faecal calprotectin should be considered during the pandemic. Prioritising access to endoscopy in the post-pandemic period should be guided by control of COVID-19 in the local community and availability of manpower and personal protective equipment. Endoscopy should be considered within 3 months after the pandemic for patients with a past history of dysplasia and endoscopic resection for dysplastic lesion. Endoscopy should be considered 3–6 months after the pandemic for assessment of postoperative recurrence or new biologic initiation. Endoscopy can be postponed until after 6 months of pandemic for routine IBD surveillance and assessment of mucosal healing.